跳至主要内容
临床试验/NCT05937269
NCT05937269进行中(未招募)1 期

Assessing Impact of Early Physiotherapy on Lymphatic Dysfunction in Head and Neck

The University of Texas Health Science Center, Houston2 个研究点 分布在 1 个国家目标入组 14 人开始时间: 2023年10月12日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
14
试验地点
2
主要终点
Incidence/Severity of lymphedema

研究概览

简要总结

The goal of this clinical trial is to learn if treating the lymphatics in head and neck cancer survivors before clinical diagnosis of lymphedema will prevent its development or progression. The main questions it aims to answer are:

  • Does early lymphatic treatment, before onset of clinical symptoms, prevent the development of head and neck lymphedema?
  • Does dermal lymphatic backflow provide an early indication of lymphedema and its response to treatment?

Over the course of one year, participants will undergo several sessions near-infrared fluorescence lymphatic imaging to assess whether they have abnormal dermal lymphatic backflow following head and neck cancer treatment. Subjects will be divided into two groups, a treated and a control group. The treated group will be asked to complete daily sessions of pneumatic compression therapy at home, while the control group will receive standard-of-card treatment after clinical diagnosis of lymphedema. Researchers will compare the incidence of lymphedema between the two groups to see if treatment before diagnosis prevents the development and progression of head and neck lymphedema.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Participants must be 18 years of age or older
  • Participants must have previously been diagnosed with head and neck cancer and undergone surgery and radiation as part of their standard-of-care treatment plan
  • Participants must be ≥ 4 weeks but less than 3 months post-radiation therapy at enrollment
  • Female participants of childbearing potential must have a negative urine pregnancy test ≤ 36 hours prior to study drug administration
  • Female participants of childbearing potential must agree to use a medically accepted method of contraception for a period of one month after each imaging session
  • Male participants must agree to shave facial hair on imaging days
  • Participants must be willing and able to independently use the pneumatic compression device at home daily for up to 12 months as directed by study personnel.

排除标准

  • Persons who are pregnant or breast-feeding
  • Females of child-bearing potential, who do not agree to use an approved contraceptive for one month after each imaging session
  • Persons who do not meet inclusion criteria
  • Iodine allergy
  • Persons with a chest circumference of 150 cm or more
  • Uncontrolled hyperthyroidism or parathyroidism (for which an endocrinologist recommends against neck compression)
  • Carotid sinus hypersensitivity syndrome
  • Symptomatic carotid artery disease, as manifested by a recent transient ischemic attack (within 30 days), ischemic stroke or amaurosis fugax (monocular visual ischemic symptoms or blindness)
  • Symptomatic bradycardia in the absence of a pacemaker or internal jugular venous thrombosis (within 3 months)
  • Increased intracranial pressure or other contraindication to internal or external jugular venous compression
  • Acute radiation dermatitis, unhealed surgical scar, unhealed or open wound(s), surgical flap less than 6 to 8-weeks post-operative
  • Facial or head and neck dermal metastasis
  • Acute facial infection (e.g., facial, or parotid gland abscess)
  • Heart failure (acute pulmonary edema, decompensated acute heart failure)
  • Acute venous disease (acute thrombophlebitis, acute deep venous thrombosis, acute pulmonary embolism)
  • Severe peripheral artery disease (critical limb ischemia including ischemic rest pain, arterial wounds, or gangrene)
  • Active skin or limb infection/inflammatory disease (acute cellulitis, other uncontrolled skin, or untreated inflammatory skin disease)
  • Any condition where increased venous and lymphatic return is undesirable

结局指标

主要结局

Incidence/Severity of lymphedema

时间窗: 12 months

The incidence of lymphedema between the control and treated groups will be compared.

次要结局

  • Change in area of dermal lymphatic backflow(12 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

John Rasmussen

Associate Professor

The University of Texas Health Science Center, Houston

研究点 (2)

Loading locations...

相似试验

Assessing Impact of Early Physiotherapy on Lymphatic... | 临床试验